{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:49:09Z","timestamp":1793566149091,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tjpad.2026.100541","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:57:18Z","timestamp":1773745038000},"page":"100541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-5314","authenticated-orcid":false,"given":"Atsushi","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-8686","authenticated-orcid":false,"given":"Yukinori","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuyo","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6456-5938","authenticated-orcid":false,"given":"Akira","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Sumitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6747-3095","authenticated-orcid":false,"given":"Mika","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tjpad.2026.100541_bib0001","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100541_bib0002","series-title":"Clinical practice guideline for dementia 2017","year":"2017"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100541_bib0003","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","article-title":"Alzheimer's disease: epidemiology and clinical progression","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.tjpad.2026.100541_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.937486","article-title":"Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019","volume":"14","author":"Li","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.tjpad.2026.100541_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100541_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100541_bib0007","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.tjpad.2026.100541_bib0008","unstructured":"Eisai Co., Ltd. Leqembi\u00ae (lecanemab) for intravenous infusion. Bunkyo-ku, Japan [Japanese], https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/170033_1190408A1025_1_02; 2023 (updated June 2024) [accessed 2 January 2026]."},{"key":"10.1016\/j.tjpad.2026.100541_bib0009","unstructured":"Eli LillyJapan K.K. Kisunla\u00ae (donanemab) for intravenous infusion. Kobe, Japan [Japanese], https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/530471_1190409A1020_1_04 ; 2024 (updated August 2025) [accessed 2 January 2026]."},{"issue":"3","key":"10.1016\/j.tjpad.2026.100541_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030952","article-title":"Protofibrils of amyloid-\u03b2 are important targets of a disease-modifying approach for Alzheimer's disease","volume":"21","author":"Ono","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100541_bib0011","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100541_bib0012","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13195-022-00995-9","article-title":"Correction to: a randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-a\u03b2 protofibril antibody","volume":"14","author":"Swanson","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100541_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100160","article-title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","volume":"12","author":"Chen","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100541_bib0014","unstructured":"Eisai Co., Ltd. Guide for appropriate use: leqembi\u00ae (lecanemab) for intravenous infusion. Bunkyo-ku, Japan [Japanese], https:\/\/www.pmda.go.jp\/RMP\/www\/170033\/4f6e6c58-f13c-47dc-a64d-2cec1f754a72\/170033_11904A5A1025_01_002RMPm.pdf; 2023 [accessed 2 January 2026]."},{"issue":"11","key":"10.1016\/j.tjpad.2026.100541_bib0015","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The clinical dementia rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"3+4","key":"10.1016\/j.tjpad.2026.100541_bib0016","first-page":"103","article-title":"Standardization of the clinical dementia rating-japanese (CDR-J) to clarify problems with the study of the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative (J-ADNI)","volume":"25","author":"Sugishita","year":"2023","journal-title":"Jpn J Cogn Neurosci"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100541_bib0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100541_bib0018","first-page":"91","article-title":"The validity and reliability of the Japanese version of the mini-mental state examination (MMSE-J) with the original procedure of the attention and calculation task (2001)","volume":"20","author":"Sugishita","year":"2018","journal-title":"Jpn J Cogn Neurosci"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100541_bib0019","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100541_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100541_bib0021","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100541_bib0022","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center","volume":"11","author":"Shields","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100541_bib0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100541_bib0024","series-title":"Alzheimer's Association International Conference (AAIC) 2025","article-title":"Two-year real-world study of LEQEMBI\u00ae in the United States","year":"2025"},{"key":"10.1016\/j.tjpad.2026.100541_bib0025","article-title":"Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study","author":"Li","year":"2025","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100541_bib0026","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321984","article-title":"Apolipoprotein E \u03b54 prevalence in Alzheimer's disease patients varies across global populations: a systematic literature review and meta-analysis","volume":"31","author":"Crean","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.tjpad.2026.100541_bib0027","article-title":"Amyloid-related imaging abnormalities (ARIA) in the context of Alzheimer\u2019s disease and amyloid-targeting therapies: an introduction for advanced practice providers","author":"Schreiber","year":"2025","journal-title":"Ther Pract"},{"issue":"10","key":"10.1016\/j.tjpad.2026.100541_bib0028","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s43587-025-00980-5","article-title":"A Japanese registry for optimizing the safe use of anti-amyloid therapies for Alzheimer's disease in Japan","volume":"5","author":"Iwatsubo","year":"2025","journal-title":"Nat Aging"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:02:26Z","timestamp":1792724546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2274580726000658"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100541","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim analysis of all-case post-marketing surveillance study in Japan: lecanemab in patients with early Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100541"}}